ACXP
Price
$2.03
Change
-$0.01 (-0.49%)
Updated
Apr 24, 6:59 PM EST
15 days until earnings call
IKT
Price
$1.87
Change
+$0.29 (+18.35%)
Updated
Apr 24, 6:59 PM EST
Ad is loading...

ACXP vs IKT ᐉ Comparison: Which is Better to Invest?

Header iconACXP vs IKT Comparison
Open Charts ACXP vs IKTBanner chart's image
Acurx Pharmaceuticals
Price$2.03
Change-$0.01 (-0.49%)
Volume$11.3K
CapitalizationN/A
Inhibikase Therapeutics
Price$1.87
Change+$0.29 (+18.35%)
Volume$47.18K
CapitalizationN/A
View a ticker or compare two or three
ACXP vs IKT Comparison Chart

Loading...

ACXPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
IKTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ACXP vs. IKT commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACXP is a Hold and IKT is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (ACXP: $2.04 vs. IKT: $1.58)
Brand notoriety: ACXP and IKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACXP: 34% vs. IKT: 138%
Market capitalization -- ACXP: $31.99M vs. IKT: $10.23M
ACXP [@Biotechnology] is valued at $31.99M. IKT’s [@Biotechnology] market capitalization is $10.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $557.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACXP’s FA Score shows that 1 FA rating(s) are green whileIKT’s FA Score has 1 green FA rating(s).

  • ACXP’s FA Score: 1 green, 4 red.
  • IKT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ACXP and IKT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACXP’s TA Score shows that 5 TA indicator(s) are bullish while IKT’s TA Score has 3 bullish TA indicator(s).

  • ACXP’s TA Score: 5 bullish, 4 bearish.
  • IKT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ACXP is a better buy in the short-term than IKT.

Price Growth

ACXP (@Biotechnology) experienced а +22.89% price change this week, while IKT (@Biotechnology) price change was -25.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.41%. For the same industry, the average monthly price growth was -3.09%, and the average quarterly price growth was +1263.37%.

Reported Earning Dates

ACXP is expected to report earnings on Aug 12, 2024.

IKT is expected to report earnings on Nov 14, 2023.

Industries' Descriptions

@Biotechnology (+0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ACXP with price predictions.
OPEN
A.I.dvisor published
a Summary for IKT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ACXP($32M) has a higher market cap than IKT($10.2M). IKT YTD gains are higher at: 24.409 vs. ACXP (-46.736).
ACXPIKTACXP / IKT
Capitalization32M10.2M314%
EBITDAN/AN/A-
Gain YTD-46.73624.409-191%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
ACXPIKT
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ACXPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
IKTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NCTY6.510.26
+4.16%
The9 Limited
BRZE40.791.11
+2.80%
Braze
GLUE5.540.04
+0.73%
Monte Rosa Therapeutics
UMH15.590.05
+0.32%
UMH Properties
KVUE19.37-0.21
-1.07%
Kenvue

ACXP and

Correlation & Price change

A.I.dvisor tells us that ACXP and TSHA have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACXP and TSHA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACXP
1D Price
Change %
ACXP100%
+3.03%
TSHA - ACXP
26%
Poorly correlated
+2.85%
COGT - ACXP
26%
Poorly correlated
-2.25%
CRVO - ACXP
25%
Poorly correlated
+1.67%
BOLT - ACXP
24%
Poorly correlated
N/A
MNMD - ACXP
24%
Poorly correlated
+2.19%
More

IKT and

Correlation & Price change

A.I.dvisor tells us that IKT and VERV have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IKT and VERV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IKT
1D Price
Change %
IKT100%
+15.33%
VERV - IKT
33%
Poorly correlated
-0.43%
EVAX - IKT
30%
Poorly correlated
-1.19%
BPTH - IKT
30%
Poorly correlated
-8.05%
CYTK - IKT
25%
Poorly correlated
-1.09%
CDTX - IKT
24%
Poorly correlated
-0.27%
More